The Diagnostic Value of Serum HE4 and CA-125 and ROMA Index in Ovarian Cancer

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2016 Jun 28

PMID 27347403

Citations 38

Authors

S U Wei

Hui Li

Bei Zhang

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is a common malignancy of the female reproductive system. Tumor markers serve as tools in the diagnosis of the disease. The aim of the present study was to determine the diagnostic value of sera levels of carbohydrate antigen-125 (CA-125), human epididymis protein 4 (HE4) as well as the area under the curve of the receiver operating characteristic (ROC) and the risk of ovarian malignancy algorithm (ROMA) index in ovarian cancer. The sera were measured using an electrochemiluminescence immunoassay on 158 individuals (64 patients with ovarian cancer, 64 with ovarian benign tumor and 30 healthy individuals) between September 2013 and May 2015. The results showed that levels of HE4 and CA-125 in the sera of the ovarian benign tumor group as well as their ROMA index were significantly higher (P<0.05) than those of the ovarian benign tumor and control groups, regardless of pre- or postmenopausal status. However, the level of CA-125 was significantly higher (P<0.05) in the ovarian benign tumor group compared with the healthy group, while the level of HE4 was similar in the two groups. The sensitivity of the ROMA index was higher (P<0.01) with detection of HE4 and CA-125. In the ovarian cancer group, the areas under ROC curves of ROMA, HE4 and CA-125 were 0.994, 0.990 and 0.941, respectively. The specificity and positive predictive value of HE4 in the premenopausal ovarian cancer group reached 98.36 and 95%, respectively. In conclusion, the results showed that the serum level of HE4 and the ROMA index are important indicators in the diagnosis of ovarian cancer. However, in addition to HE4 and CA-125 detection, the ROMA index is extremely valuable in improving the diagnostic efficiency of ovarian cancer.

Citing Articles

Advances and challenges in the use of liquid biopsy in gynaecological oncology.

Zhang Y, Tian L Heliyon. 2024; 10(20):e39148.

PMID: 39492906 PMC: 11530831. DOI: 10.1016/j.heliyon.2024.e39148.

Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.

Choi J, Kim H, Kwon H, Lee E, Cho H, Chung J Br J Cancer. 2023; 129(7):1184-1194.

PMID: 37596406 PMC: 10539369. DOI: 10.1038/s41416-023-02355-2.

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?.

Behnamfar F, Zafarbakhsh A, Ahmadian N Adv Biomed Res. 2023; 12:156.

PMID: 37564454 PMC: 10410412. DOI: 10.4103/abr.abr_264_22.

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.

Shittu K, Rabiu K, Akinola O, Ahmed S, Adewunmi A Ecancermedicalscience. 2023; 17:1568.

PMID: 37533954 PMC: 10393307. DOI: 10.3332/ecancer.2023.1568.

Integration of Single-Cell Transcriptomics With a High Throughput Functional Screening Assay to Resolve Cell Type, Growth Kinetics, and Stemness Heterogeneity Within the Comma-1D Cell Line.

Dave A, Nekritz E, Charytonowicz D, Beaumont M, Smith M, Beaumont K Front Genet. 2023; 13:894597.

PMID: 36630696 PMC: 9237515. DOI: 10.3389/fgene.2022.894597.

References

Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W . Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S145-60. DOI: 10.1016/S0020-7292(06)60032-5. View

Toss A, De Matteis E, Rossi E, Casa L, Iannone A, Federico M . Ovarian cancer: can proteomics give new insights for therapy and diagnosis?. Int J Mol Sci. 2013; 14(4):8271-90. PMC: 3645742. DOI: 10.3390/ijms14048271. View

Holcomb K, Vucetic Z, Miller M, Knapp R . Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011; 205(4):358.e1-6. DOI: 10.1016/j.ajog.2011.05.017. View

Moore R, McMeekin D, Brown A, DiSilvestro P, Miller M, Allard W . A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2008; 112(1):40-6. PMC: 3594094. DOI: 10.1016/j.ygyno.2008.08.031. View

Levanon K, Crum C, Drapkin R . New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008; 26(32):5284-93. PMC: 2652087. DOI: 10.1200/JCO.2008.18.1107. View

Karlsen M, Sandhu N, Hogdall C, Christensen I, Nedergaard L, Lundvall L . Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012; 127(2):379-83. DOI: 10.1016/j.ygyno.2012.07.106. View

Jacobs I, Bast Jr R . The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4(1):1-12. DOI: 10.1093/oxfordjournals.humrep.a136832. View

Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M . Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(9):2480-7. PMC: 2632599. DOI: 10.1158/1055-9965.EPI-08-0150. View

Moore R, Brown A, Miller M, Badgwell D, Lu Z, Allard W . Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2):196-201. PMC: 3594093. DOI: 10.1016/j.ygyno.2008.04.002. View

10.

Urban N, McIntosh M, Andersen M, Karlan B . Ovarian cancer screening. Hematol Oncol Clin North Am. 2003; 17(4):989-1005, ix. DOI: 10.1016/s0889-8588(03)00063-7. View

11.

Yancik R . Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993; 71(2 Suppl):517-23. DOI: 10.1002/cncr.2820710205. View

12.

Enakpene C, Omigbodun A, Goecke T, Odukogbe A, Beckmann M . Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res. 2009; 35(1):131-8. DOI: 10.1111/j.1447-0756.2008.00869.x. View

13.

Folk J, Botsford M, Musa A . Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol. 1995; 57(2):178-82. DOI: 10.1006/gyno.1995.1121. View

14.

Smith L, Oi R . Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv. 1984; 39(6):313-28. View

15.

Park Y, Kim Y, Lee E, Lee J, Kim H . Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2011; 130(5):1136-44. DOI: 10.1002/ijc.26129. View

16.

Sandri M, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S . Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2012; 128(2):233-8. DOI: 10.1016/j.ygyno.2012.11.026. View

17.

Molina R, Escudero J, Auge J, Filella X, Foj L, Torne A . HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32(6):1087-95. PMC: 3195682. DOI: 10.1007/s13277-011-0204-3. View

18.

Moore R, Jabre-Raughley M, Brown A, Robison K, Miller M, Allard W . Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010; 203(3):228.e1-6. PMC: 3594101. DOI: 10.1016/j.ajog.2010.03.043. View

19.

Zhang Z, Bast Jr R, Yu Y, Li J, Sokoll L, Rai A . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64(16):5882-90. DOI: 10.1158/0008-5472.CAN-04-0746. View

20.

Kadija S, Stefanovic A, Jeremic K, Radojevic M, Nikolic L, Markovic I . The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012; 22(2):238-44. DOI: 10.1097/IGC.0b013e318234f852. View